Found that new type of cervical cancer subtype individualized cancer therapy is expected to be developed
January 17, 2017 Source: Bio Valley
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Recently, a research report published in the international magazine Oncotarget , researchers from the University of South Carolina identified a new type of cervical cancer subtype similar to most cervical cancer. It is also induced by human papillomavirus (HPV), but its growth is not under the command of HPV, suggesting that targeting specific tumor genomic pathways may help improve patient outcomes and develop new targets. Sexual therapy.
Researcher Banister pointed out that we currently use a combination of chemotherapy and radiotherapy to treat cervical cancer patients, and this treatment can help a large number of patients, but standard therapy has no effect on about one-third of patients; we A new class of cervical cancer subtypes have been discovered that have completely different genetic traits, and treatment in these patients seems to be based on other methods.
In the article, the researchers analyzed 255 cervical cancer samples from the Cancer Genome Atlas project and found that HPV oncogenes that are thought to be essential for cervical cancer development are only at HPV high activity levels or HPV. Expression is performed at the level of inactivation. In previous studies, researchers found the presence of HPV in the body of patients with head and neck cancer, so they speculated whether the degree of HPV inactivation of cervical cancer originated from virus-driven cancer, the researchers confirmed in this study With this speculation, they discovered a new molecular genetic mechanism that can drive the evolution of HPV-inactivated cancer.
In addition to HPV oncogene expression, the investigators also noted that there are other significant differences between HPV-inactivated cervical cancer and HPV-active cervical cancer, and that two types of cervical cancer patients are found to survive. Value, DNA methylation, mean age at diagnosis of disease, and significant differences in gene expression characteristics. The researchers analyzed the frequency of somatic mutations in all human genes and found that 19 cancer-driven genes showed significantly higher mutation rates in HPV-inactivated patients compared to HPV activity levels. The difference may indicate that the HPV oncogene appears to be able to remove the function of the mutant gene in regulating tumor cell growth.
For example, HPV-inactivated tumors are 17 times more likely to have mutations in the TP53 gene than HPV-active cervical cancer, so therapies targeting TP53 mutations seem to bring better HPV inactivated tumors. The therapeutic effect. Finally, the researcher Banister said that doctors engaged in the management of cervical cancer patients should detect the expression of HPV oncogenes in patients with tumors, and should also consider individualized therapy that relies on HPV activity, the expression level of immunoregulatory genes in HPV-active tumors. Higher, and will respond to immunological checkpoint inhibitor therapy. In contrast, HPV-inactivated tumors often undergo mutations in the PIK3CA/PTEN/AKT pathway, suggesting that AKT kinase inhibitors seem to be effective Such patients.
Wenzhou Celecare Medical Instruments Co.,Ltd , https://www.wzcelecare.com